Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 74 of the 148 sources its claims cite were checked for support.

Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor

Open access
Jamal, Fares, Elshaer, Amani, Alatout, Mayar H., Odeh, Nour B., Youssef, Amal, Abo Abdullah, Humam, Elmasry, Sandra, Shahin, Tala, Abdul Nabi, Hussein, Worden, Astin R., Malik, Talha A., Lizaola-Mayo, Blanca C. · 2025 · Biomedicines

Abstract

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease marked by cholestasis and progressive fibrosis. While ursodeoxycholic acid (UDCA) remains the first-line therapy, approximately 30-40% of patients have an inadequate biochemical response, increasing the risk of disease progression. Obeticholic acid (OCA), a potent farnesoid X receptor (FXR) agonist, was the first second-line agent approved by the only Food and Drug Administration (FDA) and has demonstrated moderate biochemical efficacy but limited tolerability due to dose-dependent pruritus and safety concerns in cirrhosis. Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, showed substantial alkaline phosphatase (ALP) reductions when added to UDCA, although its long-term benefit remains unconfirmed in large-scale trials and its use remains off-label in the United States, unlike FDA-approved agents. Seladelpar, a selective peroxisome proliferator-activated receptor delta (PPAR-δ) agonist, and elafibranor, a dual PPAR-α/δ agonist, have both recently received FDA accelerated approval after demonstrating significant improvements in ALP, biochemical response rates, and pruritus relief in phase 3 trials. This review summarizes these second-line therapies' mechanisms, efficacy, safety, and limitations emphasizing the need for individualized treatment decisions and ongoing research into long-term clinical outcomes.

Overview

CoChat Summary

TL;DR

This comparative review summarizes mechanisms, efficacy, safety, and limitations of second-line therapies for primary biliary cholangitis: obeticholic acid, fibrates, seladelpar, and elafibranor. It concludes that all improve biochemical endpoints, but long-term outcome data remain limited and treatment should be individualized.

Key findings

  • Obeticholic acid (OCA): In POISE, the primary endpoint was achieved by 46% of the 5–10 mg group and 47% of the 10 mg group vs 10% with placebo (p < 0.001). In an observational study of 191 patients, median reductions at 12 months were ALP −32.3%, ALT −31.4%, and bilirubin −11.2%; cirrhosis was associated with lower response (29.5% vs 49.2%; p = 0.01) and higher discontinuation (30% vs 12%; p = 0.004). Safety concerns include dose-dependent pruritus and a 3.9-fold increased risk of hepatic decompensation in PBC-related cirrhosis; annual cost was approximately $69,000, with an ICER of $473,400 per QALY.
  • Fibrates: In BEZURSO, 24-month biochemical response occurred in 31% with bezafibrate vs 0% with placebo (p < 0.001), and ALP normalization in 67% vs 2% (p < 0.001). A randomized trial of fenofibrate plus UDCA reported Barcelona response in 81.4% vs 64.3% with UDCA alone (p = 0.048). Fibrates remain off-label for PBC in the United States; adverse events included myalgia (20% vs 10%) and reversible creatinine elevation.
  • Seladelpar: In ENHANCE at 3 months, composite biochemical response was 78.2% with 10 mg and 57.1% with 5 mg vs 12.5% with placebo (p < 0.0001); ALP < 1.67 × ULN occurred in 95% and 95% vs 23% (p < 0.0001). In RESPONSE, composite response was 61.7% vs 20.0% (p < 0.001), ALP normalization 25% vs 0% (p < 0.001), and pruritus NRS change −3.2 vs −1.7 (p = 0.005). ASSURE reported sustained composite response in 72% and new response in 94% of crossover patients at 12 months.
  • Elafibranor: In a phase 2 trial, ALP decreased by −48.3% with 80 mg and −40.6% with 120 mg vs +3.2% with placebo (p < 0.001 for both); composite endpoint was achieved by 67% and 79% vs 6.7%. In ELATIVE, biochemical response occurred in 51% vs 4% with placebo (p < 0.001), ALP normalization in 15% vs 0% (p < 0.002), and WI-NRS change did not differ significantly between groups. It received FDA accelerated approval in 2024.

Methods

  • Narrative comparative review; no systematic review methods, search strategy, or formal risk-of-bias assessment are described.
  • Synthesizes published clinical trials, observational studies, and guidelines for OCA, fibrates, seladelpar, and elafibranor, including POISE, D’Amato, Gomez, BEZURSO, fenofibrate trials, ENHANCE, RESPONSE, ASSURE, elafibranor phase 2, and ELATIVE.
  • Main analysis is qualitative comparison of mechanisms, biochemical efficacy, pruritus effects, safety, and regulatory status; no meta-analysis or pooled statistics are reported.

Limitations

  • The paper states that the evidence base is largely driven by surrogate biochemical endpoints, with limited long-term data on fibrosis progression, transplantation, or survival, constraining firm treatment algorithms.
  • The paper notes that trials excluded patients with decompensated cirrhosis or advanced liver failure and autoimmune overlap syndromes, limiting generalizability; ELATIVE enrolled mostly white patients, with racial minorities underrepresented and ethnicity data not recorded.
  • Evident from the text: as a narrative review without a described systematic search or formal quality assessment, selection and synthesis may be subject to bias.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/biomedicines13102335

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Mechanisms of Action of Novel Agents in Primary Biliary Cholangitis.
Figure 1 Mechanisms of Action of Novel Agents in Primary Biliary Cholangitis.CC BY · PubMed Central

Verification

Claims the paper makes

64 Valid · 1 Not valid · 56 Not checked · 14 Own results and interpretations

80 more claims · 34 with their cited sources checked

Create a free account to see all 135 claims and to verify the 6 references still open.

See all claims — free account
  • It may state two separate claims as one. 47
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 46 references

Cited by

See all 6

Metadata

Authors
Jamal, F., Elshaer, A., Alatout, M. H., Odeh, N. B., Youssef, A., Abo Abdullah, H., Elmasry, S., Shahin, T., Abdul Nabi, H., Worden, A. R., Malik, T. A., & Lizaola-Mayo, B. C.
Affiliations
  • Mayo Clinic (US)
  • Department of Cardiology, Mayo Clinic, Phoenix, AZ 85054, USA
  • Department of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ 85054, USA
Corresponding author
Jamal, Fares
Venue
Biomedicines
Publisher
MDPI AG
Published
2025-09-24
Volume
13
Issue
10
Pages
2335
ISSN
2227-9059 (ISSN-L)
OpenAlex
W4414517587
Cited by
6
References
46
Citations by year
2026: 6
FWCI
0.88
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords
primary biliary cirrhosis, second-line therapy, obeticholic acid, fibrates, fenofibrate, seladelpar, elafibranor, farnesoid X receptor agonist, PPARα agonist, PPARδ agonist, ursodeoxycholic acid, cholestasis, pruritus, alkaline phosphatase, liver fibrosis, drug safety and tolerability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor. https://app.cochat.ai/papers/10.3390/biomedicines13102335
The paper
Jamal, F., Elshaer, A., Alatout, M. H., Odeh, N. B., Youssef, A., Abo Abdullah, H., Elmasry, S., Shahin, T., Abdul Nabi, H., Worden, A. R., Malik, T. A., & Lizaola-Mayo, B. C. (2025). Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor. Biomedicines. https://doi.org/10.3390/biomedicines13102335

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.